{"pageContent": "Introduction: The ReIMAGINE Consortium was conceived to develop risk-stratification models that might incorporate the full range of novel prostate cancer (PCa) diagnostics (both commercial and academic).", "metaData": {"source": "The current role of imaging for prostate brachytherapy\nhttps://pubmed.ncbi.nlm.nih.gov/17339141/"}}